The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2020

Filed:

Jul. 20, 2017
Applicant:

Theravectys, Paris, FR;

Inventors:

Mohamad Jamiluddin, Frederick, MD (US);

Ana Bejanariu, Boulogne-Billancourt, FR;

Emeline Sarry, Malakoff, FR;

Assignee:

THERAVECTYS, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/29 (2006.01); A61P 31/14 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/29 (2013.01); A61K 39/292 (2013.01); A61P 31/14 (2018.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); C07K 2319/00 (2013.01); C12N 2740/15011 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/16011 (2013.01); C12N 2740/16043 (2013.01); C12N 2799/027 (2013.01); C12N 2840/203 (2013.01);
Abstract

The invention relates to nucleic acids, including lentiviral vectors and lentiviral vector particles, encoding at least one Hepatitis B virus (HBV) envelop surface of genotypes A and/or C antigen, at least one polymerase of genotypes A and/or C antigen, at least one HBX protein of genotypes A and/or C antigen, at least one HBV consensus core of genotypes A and/or C antigen, and at least one HBV consensus core MHCI and MHCII epitopes of genotypes A and/or C antigen. The invention encompasses these lentiviral vectors and lentiviral vector particles, methods of making the vectors, and their use, including medicinal uses. The lentiviral vectors and lentiviral vector particles are for use in administering to humans to induce immune responses against the HBV antigens.


Find Patent Forward Citations

Loading…